Xanthigen and Its Impact on Weight and Metabolic Health

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Obesity & Overweight

In brief

Randomized, controlled, triple-blind clinical trial with three parallel arms based on the product consumed (low-dose experimental product, high-dose experimental product, and placebo product) and conducted at a single center to measure the efficacy of a product (Xanthigen®) on overweight or obesity during 16 weeks of consumption.

Key facts

Study ID

NCT07519980

Run by

Universidad Católica San Antonio de Murcia

People needed

180

Starts

2026-02-02

Expected to finish

2026-09-15

Last updated by the study team

2026-05-07

Who can join

Age: 20 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The subject is able and willing to follow the study protocol procedures to sign the informed consent form prior to the evaluations.
• Participants must be between 20 and 50 years of age at the time of consent.
• The subject is in good physical and mental health as determined by medical history, physical examination, electrocardiogram, vital signs, biochemistry, and hematology results.
• Participants must have a BMI between 27 and 29.9 kg/cm2.
• Desire to lose weight.

You may not qualify if…

• Relevant medical history or presence of any medical condition that could interfere with this study, such as a previous diagnosis of diabetes, hypertension, hyperlipidemia, cardiovascular disease, thyroid disease, asthma, arthritis, or inflammatory conditions.
• Fasting blood sugar levels greater than 125 mg/dL and/or total cholesterol levels greater than or equal to 240 mg/dL.
• Blood pressure levels below 90/140 mm Hg (diastolic/systolic).
• Chronic intake of medications/dietary supplements with an impact on body weight or body composition or lipid-modifying products (e.g., protein shakes, statins, omega-3 fatty acids, etc.) 2 months prior to selection or during the study.
• Known allergy/sensitivity to any of the components of the investigational product.
• Change in hormonal contraception or any use of hormone replacement therapy (HRT) during or at least 3 months prior to the study (if female).
• Women of childbearing age who are pregnant or intend to become pregnant during the study period.
• Use of any dietary supplements (except mineral supplements, e.g., Ca, Mg).
• Participation in any weight loss intervention or recent change in body weight > 4.5 kg during the last 9 months.
• History and/or presence of eating disorders such as bulimia, anorexia nervosa, or binge eating, as determined by the investigator.
• Consumption of any dietary supplements (except mineral supplements, e.g., Ca, Mg).
• Participation in any weight loss program or recent change in body weight > 4.5 kg during the last 9 months.
• History and/or presence of eating disorders such as bulimia, anorexia nervosa, binge eating, as determined by the investigator.
• Individuals who currently participate in aerobic exercise more than 4 times per week, or more than 2.5 hours per week.
• Vegan lifestyle.
• Current smoker or user of nicotine products or cessation of smoking within 1 year of the screening date.
• Gastrointestinal diseases/conditions (colitis ulcers, Crohn's disease, peptic ulcers, celiac disease).

Where it is running

• UCAM HiTech, Sport & Health Innovation Hub — Murcia, Murcia, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.